NM_000344.4(SMN1):c.827A>G (p.Tyr276Cys)

Base Editing (BE4max) via AAV9 delivery is a rationale-driven therapeutic strategy for Spinal muscular atrophy type 1 (SMN1-related) targeting the SMN1 c.827A>G (p.Tyr276Cys) variant (Pathogenic, missense variant). The editing system (BE4max (cytosine base editor)) converts the pathogenic C to T (or G to A on the target strand), restoring the wild-type codon. Target tissue: CNS. Therapeutic goal: Correct SMN1 loss-of-function at 5q13.2 in spinal anterior horn motor neurons to restore SMN protein and prevent progressive motor neuron degeneration.. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: SMN1 NM_000344.4(SMN1):c.827A>G (p.Tyr276Cys) is classified as Pathogenic (ClinVar variation ID 3239716). Molecular consequence: missense variant. Protein change: Y244C, Y276C. 2. Epidemiology: Autosomal recessive 5q spinal muscular atrophy has an incidence of roughly 1 in 10,000–11,000 live births with carrier frequency about 1 in 50; SMA type 1 is the most common and severe form, with onset before 6 months and historically death or permanent ventilation before age 2 without treatment. 3. Standard of care: Current disease-modifying options for SMN1-related SMA include intrathecal nusinersen, systemic gene replacement with onasemnogene abeparvovec, and oral risdiplam, all of which increase functional SMN protein via SMN2 splicing modulation or SMN1 gene transfer; multidisciplinary supportive care (vent 4. Pipeline: Multiple SMN-targeted therapies are fully approved (nusinersen, risdiplam, onasemnogene) with ongoing Phase II/III optimization and combination trials; preclinical programs are exploring in vivo base editing and CRISPR strategies targeting SMN1/SMN2 in motor neurons, and CRISPR-based therapies for r 5. CBE clinical validation: BE4max (Koblan et al. 2018) is the gold-standard cytosine base editor. Multiple CBE programs are in clinical development for liver and hematologic targets.

1. No published data specifically correcting SMN1 c.827A>G (p.Tyr276Cys) with Base Editing (BE4max); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 4. Delivery to CNS tissue remains a major translational bottleneck. Current vectors have limited transduction efficiency in these compartments. 4. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.